Search

Your search keyword '"McFarlane, P.A."' showing total 12 results
Start Over Author "McFarlane, P.A."
12 results on '"McFarlane, P.A."'

3. Canadian Consensus Recommendations on the Management of Venous Thromboembolism in Patients with Cancer. Part 1: Prophylaxis

Author

Easaw, J.C., primary, Shea–Budgell, M.A., additional, Wu, C.M.J., additional, Czaykowski, P.M., additional, Kassis, J., additional, Kuehl, B., additional, Lim, H.J., additional, MacNeil, M., additional, Martinusen, D., additional, McFarlane, P.A., additional, Meek, E., additional, Moodley, O., additional, Shivakumar, S., additional, Tagalakis, V., additional, Welch, S., additional, and Kavan, P., additional

Published
2015
Full Text
View/download PDF

4. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment

Author

Easaw, J.C., primary, Shea-Budgell, M.A., additional, Wu, C.M.J., additional, Czaykowski, P.M., additional, Kassis, J., additional, Kuehl, B., additional, Lim, H.J., additional, MacNeil, M., additional, Martinusen, D., additional, McFarlane, P.A., additional, Meek, E., additional, Moodley, O., additional, Shivakumar, S., additional, Tagalakis, V., additional, Welch, S., additional, and Kavan, P., additional

Published
2015
Full Text
View/download PDF

6. 750 Are Lifestyle Modifications Being Appropriately Recommended in the Canadian Primary Care Practice to Manage Elevated Cardiometabolic Risk?

Author

Teoh, H., primary, Després, J.P., additional, Fitchett, D.H., additional, Galluzzi, A., additional, Goldin, L., additional, Goodman, S.G., additional, Harris, S.B., additional, Langer, A., additional, Lonn, E.M., additional, Mancini, G.B.J., additional, McFarlane, P.A., additional, Poirier, P., additional, Rabasa-Lhoret, R., additional, and Leiter, L.A., additional

Published
2012
Full Text
View/download PDF

7. 247 How Do Canadian Primary Care Physicians in Family Health Teams Compare With Those in Solo-Physician Practices in Their Assessment and Management of Patients With Elevated Cardiometabolic Risk?

Author

Teoh, H., primary, Després, J.P., additional, Fitchett, D.H., additional, Galluzzi, A., additional, Goldin, L., additional, Goodman, S.G., additional, Harris, S.B., additional, Langer, A., additional, Lonn, E.M., additional, Mancini, G.B.J., additional, McFarlane, P.A., additional, Poirier, P., additional, Rabasa-Lhoret, R., additional, and Leiter, L.A., additional

Published
2012
Full Text
View/download PDF

12. A Numerical Scale Comparison of Renal Transplant Recipient Experience with and Opinions about Calcineurin Inhibitors

Author

Prasad, G.V.R., Nash, M.M., McFarlane, P.A., and Zaltzman, J.S.

Abstract

AbstractBackground: Many studies compare the relative benefits of cyclosporine and tacrolimus with respect to graft and patient outcomes, but comparative renal transplant recipient opinion on calcineurin inhibitor (CI) use has not been directly sought. Methods: We administered a confidential clinic-distributed written questionnaire to adult single-organ recipients pertaining to CI use and related physical side effects experienced. Sixteen common immunosuppressive therapy-related side effects were rated on a 1–10 Likert numerical scale, with 1 meaning complete disagreement and 10 complete agreement with their own CI experience. Comparisons were made among recipients on cyclosporine, tacrolimus, and those with a dual drug experience. Results: The questionnaire was filled by 316 patients. The efficacy of cyclosporine and tacrolimus was considered equivalent (p = 0.99), while the overall side effect profile reported was greater for cyclosporine (p = 0.001). The side effect profile for cyclosporine was greater in the dual group than the cyclosporine-only group (p = 0.01). Cyclosporine was perceived as more difficult to swallow (p = 0.001), nephrotoxic (p = 0.005), and to cause more hypertension (p = 0.04) and hyperlipidemia (p = 0.001), while tacrolimus was perceived to be more neurotoxic (p < 0.0001), but not causing more diabetes (p = 0.64). Conclusions: Renal transplant recipients experience fewer and less severe side effects with tacrolimus. Further contemporaneous study of CI preferences in this population is warranted. Transplant centers should consider patient opinion in tailoring their own immunosuppressive strategies and regimens.Copyright © 2004 S. Karger AG, Basel

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results